DMI BioSciences Inc.
Division of Ampio Pharmaceuticals Inc.
Latest From DMI BioSciences Inc.
Don Wingerter, CEO of Ampio Pharmaceuticals, a company that discovers new uses for previously approved drugs, has been granted compassionate leave of indefinite length from all his duties to attend to the serious health problems afflicting his parents. Filling the breach is Michael Macaluso, current chair of the Ampio board of directors and lead investor in DMI BioSciences, predecessor company to Ampio.
US-based Ampio Pharmaceuticals has named Mark McGregor chief financial officer and corporate secretary. Bruce Miller, who has served in these roles since April 2010, will join the team that will advance the commercialisation of Ampio's Phase III product candidate, Zertane, which was obtained through the acquisition of DMI BioSciences in 2010. Mr Miller had served as DMI's chief executive officer and/or president since 1992. Ampio is developing proprietary drugs for metabolic, eye and kidney diseases, inflammation, CNS disease and male sexual dysfunction.
Ampio Pharmaceuticals has finalised the terms of its previously announced acquisition of DMI BioSciences in a stock purchase.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.